Advancing shared decision making for symptom monitoring in people living beyond cancer

Lauren C. Heathcote, Daniel S. Goldberg, Christopher Eccleston, Sheri L. Spunt, Laura E. Simons, Louise Sharpe, Brian D. Earp

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Wellbeing after successful cancer treatment depends on more than merely reducing the risk of disease recurrence. Cancer survival can be characterised by uncertainty, fear, and the interpretation of bodily sensations as potentially symptomatic of cancer recurrence. This fear can lead to over-vigilance about bodily sensations and precautionary visits to the doctor, both of which can increase the chance of early detection but can also increase anxiety and decrease quality of life. In this Personal View, we consider the medical, psychological, and ethical issues related to the practice of self-directed symptom monitoring after completion of cancer treatment, focusing on the role of doctor–patient communication. We ask how clinicians can account for the plurality of values that patients might have when it comes to deciding on how to manage and respond to experiences of post-cancer symptoms. We advocate a shared decision-making approach that incorporates the assessment of an individual's cancer recurrence risks as well as psychosocial considerations regarding fear of cancer recurrence and mental health. We aim to raise awareness of the potential quality-of-life implications of symptom-monitoring practices, emphasising the need for a balance between physical and psychological health in people living beyond cancer.
LanguageEnglish
Pagese556-e563
JournalThe Lancet Oncology
Volume19
Issue number10
Early online date1 Oct 2018
DOIs
StatusE-pub ahead of print - 1 Oct 2018

Fingerprint

Decision Making
Neoplasms
Fear
Recurrence
Quality of Life
Psychology
Ethics
Uncertainty
Mental Health
Survival Rate
Anxiety
Communication
Survival
Health
Therapeutics

Cite this

Heathcote, L. C., Goldberg, D. S., Eccleston, C., Spunt, S. L., Simons, L. E., Sharpe, L., & Earp, B. D. (2018). Advancing shared decision making for symptom monitoring in people living beyond cancer. The Lancet Oncology, 19(10), e556-e563. https://doi.org/10.1016/S1470-2045(18)30499-6

Advancing shared decision making for symptom monitoring in people living beyond cancer. / Heathcote, Lauren C.; Goldberg, Daniel S.; Eccleston, Christopher; Spunt, Sheri L.; Simons, Laura E.; Sharpe, Louise; Earp, Brian D.

In: The Lancet Oncology, Vol. 19, No. 10, 01.10.2018, p. e556-e563.

Research output: Contribution to journalArticle

Heathcote, LC, Goldberg, DS, Eccleston, C, Spunt, SL, Simons, LE, Sharpe, L & Earp, BD 2018, 'Advancing shared decision making for symptom monitoring in people living beyond cancer', The Lancet Oncology, vol. 19, no. 10, pp. e556-e563. https://doi.org/10.1016/S1470-2045(18)30499-6
Heathcote, Lauren C. ; Goldberg, Daniel S. ; Eccleston, Christopher ; Spunt, Sheri L. ; Simons, Laura E. ; Sharpe, Louise ; Earp, Brian D. / Advancing shared decision making for symptom monitoring in people living beyond cancer. In: The Lancet Oncology. 2018 ; Vol. 19, No. 10. pp. e556-e563.
@article{f4e6c2f692404c7996a117e0c8b48866,
title = "Advancing shared decision making for symptom monitoring in people living beyond cancer",
abstract = "Wellbeing after successful cancer treatment depends on more than merely reducing the risk of disease recurrence. Cancer survival can be characterised by uncertainty, fear, and the interpretation of bodily sensations as potentially symptomatic of cancer recurrence. This fear can lead to over-vigilance about bodily sensations and precautionary visits to the doctor, both of which can increase the chance of early detection but can also increase anxiety and decrease quality of life. In this Personal View, we consider the medical, psychological, and ethical issues related to the practice of self-directed symptom monitoring after completion of cancer treatment, focusing on the role of doctor–patient communication. We ask how clinicians can account for the plurality of values that patients might have when it comes to deciding on how to manage and respond to experiences of post-cancer symptoms. We advocate a shared decision-making approach that incorporates the assessment of an individual's cancer recurrence risks as well as psychosocial considerations regarding fear of cancer recurrence and mental health. We aim to raise awareness of the potential quality-of-life implications of symptom-monitoring practices, emphasising the need for a balance between physical and psychological health in people living beyond cancer.",
author = "Heathcote, {Lauren C.} and Goldberg, {Daniel S.} and Christopher Eccleston and Spunt, {Sheri L.} and Simons, {Laura E.} and Louise Sharpe and Earp, {Brian D.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/S1470-2045(18)30499-6",
language = "English",
volume = "19",
pages = "e556--e563",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Advancing shared decision making for symptom monitoring in people living beyond cancer

AU - Heathcote, Lauren C.

AU - Goldberg, Daniel S.

AU - Eccleston, Christopher

AU - Spunt, Sheri L.

AU - Simons, Laura E.

AU - Sharpe, Louise

AU - Earp, Brian D.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Wellbeing after successful cancer treatment depends on more than merely reducing the risk of disease recurrence. Cancer survival can be characterised by uncertainty, fear, and the interpretation of bodily sensations as potentially symptomatic of cancer recurrence. This fear can lead to over-vigilance about bodily sensations and precautionary visits to the doctor, both of which can increase the chance of early detection but can also increase anxiety and decrease quality of life. In this Personal View, we consider the medical, psychological, and ethical issues related to the practice of self-directed symptom monitoring after completion of cancer treatment, focusing on the role of doctor–patient communication. We ask how clinicians can account for the plurality of values that patients might have when it comes to deciding on how to manage and respond to experiences of post-cancer symptoms. We advocate a shared decision-making approach that incorporates the assessment of an individual's cancer recurrence risks as well as psychosocial considerations regarding fear of cancer recurrence and mental health. We aim to raise awareness of the potential quality-of-life implications of symptom-monitoring practices, emphasising the need for a balance between physical and psychological health in people living beyond cancer.

AB - Wellbeing after successful cancer treatment depends on more than merely reducing the risk of disease recurrence. Cancer survival can be characterised by uncertainty, fear, and the interpretation of bodily sensations as potentially symptomatic of cancer recurrence. This fear can lead to over-vigilance about bodily sensations and precautionary visits to the doctor, both of which can increase the chance of early detection but can also increase anxiety and decrease quality of life. In this Personal View, we consider the medical, psychological, and ethical issues related to the practice of self-directed symptom monitoring after completion of cancer treatment, focusing on the role of doctor–patient communication. We ask how clinicians can account for the plurality of values that patients might have when it comes to deciding on how to manage and respond to experiences of post-cancer symptoms. We advocate a shared decision-making approach that incorporates the assessment of an individual's cancer recurrence risks as well as psychosocial considerations regarding fear of cancer recurrence and mental health. We aim to raise awareness of the potential quality-of-life implications of symptom-monitoring practices, emphasising the need for a balance between physical and psychological health in people living beyond cancer.

U2 - 10.1016/S1470-2045(18)30499-6

DO - 10.1016/S1470-2045(18)30499-6

M3 - Article

VL - 19

SP - e556-e563

JO - The Lancet Oncology

T2 - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -